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Since the cloning of BRCA1 and BRCA2 (Miki et al, 1994;
Wooster et al, 1995), there has been considerable interest in the
population prevalence (allele frequency) and the age-specific
cumulative risk (penetrance) of mutations in these genes, and the
proportion of breast and other cancers attributable to these muta-
tions (population attributable risk or aetiological fraction). To date,
however, most information on the magnitude of the above popula-
tion characteristics of these genes has been indirect, not based on
population samples, or incomplete.
Indirect information on population characteristics has been
derived from segregation analyses of nuclear families ascertained
in case–control studies, in which the assessment of disease in rela-
tives has been based on unverified reports from cases alone and
usually restricted to first-degree relatives. The main purpose of
segregation analysis is to elucidate the most likely mode of inheri-
tance. Estimates are strongly dependent on sampling, and on the
assumptions of the underlying mathematical model which usually
attribute all of the familial aggregation of disease to genetic
factors. Because at least a proportion of the familial aggregation
of breast cancer can be explained by familial aggregation in
epidemiological risk factors, especially taking into account
misclassification and measurement error (Hopper and Carlin,
1992), segregation analyses are likely to overestimate any genetic
contribution.
Analysis of data from US nuclear families ascertained in a
case–control study of breast cancer predicted that about 1 in 150
women (confidence interval not reported) had inherited a lifetime
risk of about 90% (Claus et al, 1991). A more recent analysis of
data from US families ascertained in case–control studies of
ovarian cancer suggested an allele frequency of about 1 in 350
[95% confidence interval (CI) from 1 in 50 to 1 in 2500]
(Whittemore et al, 1997). Although it is sometimes presumed that
these estimates are fully attributable to BRCA1 (e.g. Whittemore et
al, 1997), they should be interpreted as representing the domi-
nantly inherited component of all genes involved in susceptibility
to breast cancer, including BRCA2. Analysis of population-based
samples of UK cancer families (Easton et al, 1996; Peto et al,
1996), assuming BRCA1 accounts for almost all the excess of
ovarian cancer in relatives of breast cancer patients and vice versa,
estimated that 1 in 800 women (95% CI, 1 in 500 to 1 in 2500)
inherit a BRCA1 mutation (Ford et al, 1995).
In this paper, we estimate, among those who develop breast
cancer before the age of 40 years, the proportion of women who
carry a mutation in BRCA1. Indirect information from mathemat-
ical modelling initially suggested that about 30% of such early-
onset breast cancer cases could occur in women who carry a
high-risk dominantly inherited susceptibility (Claus et al, 1991),
although recent publications have suggested that this may be more
in the order of 11% (95% CI 1–50%) (Whittemore et al, 1997), or
5% (CI, not reported) (Ford et al, 1995). It could also vary from
population to population.
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Summary The frequency, in women with breast cancer, of mutations and other variants in the susceptibility gene, BRCA1, was investigated
using a population-based case–control-family study. Cases were women living in Melbourne or Sydney, Australia, with histologically
confirmed, first primary, invasive breast cancer, diagnosed before the age of 40 years, recorded on the state Cancer Registries. Controls were
women without breast cancer, frequency-matched for age, randomly selected from electoral rolls. Full manual sequencing of the coding
region of BRCA1 was conducted in a randomly stratified sample of 91 cases; 47 with, and 44 without, a family history of breast cancer in a
first- or second-degree relative. All detected variants were tested in a random sample of 67 controls. Three cases with a (protein-truncating)
mutation were detected. Only one case had a family history; her mother had breast cancer, but did not carry the mutation. The proportion of
Australian women with breast cancer before age 40 who carry a germline mutation in BRCA1 was estimated to be 3.8% (95% Cl 0.3–12.6%).
Seven rare variants were also detected, but for none was there evidence of a strong effect on breast cancer susceptibility. Therefore, on a
population basis, rare variants are likely to contribute little to breast cancer incidence.
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The first direct evidence came from mutation screening in 80
women from a previous US case–control study of breast cancer in
women under the age of 35 (Langston et al, 1996), which found
that 7.5% (95% CI 3.8–11.4%) carried ‘definite’ germline muta-
tions. The sensitivity of the mutation detection method was
considered to be 70–80%, and although blood was available from
only one-third of eligible cases these did not appear to differ in
frequency of family history from the non-tested, interviewed
cases. A small proportion of carcinoma in situ was included, but
all six mutation carriers had invasive breast cancer. Four rare vari-
ants of unknown significance were also observed. Interestingly,
only three of the six mutation carriers, and one of the four carriers
of a rare variant, reported breast cancer in a first- or second-degree
female relative. More recently, mutation testing in another US
population-based sample of 211 cases, over-sampled for onset
before the age of 50 years, found that only three carried a mutation
(all protein-truncating), leading to a prevalence estimate of
3.3% (95% CI 0–7.2%) among white women and 0% among
African–American women (Newman et al, 1998).
We have conducted a full sequence analysis of the BRCA1
coding region (and of some non-coding regions) in a population-
based sample of women with breast cancer, stratified by family
history, and in a random, population-based sample of women
without breast cancer. Information on family history was obtained
by interviewing cases, controls and relatives, and validated where
possible. The mutation-detection approach we have used should
detect all mutations in the coding and flanking intronic regions,
including single base changes, but would not detect splicing prob-
lems due to genetic variation deep within the intronic regions or
variants in the promotor region or outside BRCA1.
SUBJECTS AND METHODS
A population-based case–control-family study of early onset
breast cancer was carried out in Melbourne and Sydney from 1992
to 1995 (Hopper et al, 1994; McCredie et al, 1998). Cases were
adult women under the age of 40 years at diagnosis of an incident,
histologically confirmed, first primary, invasive breast cancer
(ICD-9 174) identified through the Victorian and New South
Wales state cancer registries. Controls were women who had not
had breast cancer, selected from the electoral rolls (enrolment is
compulsory in Australia) using stratified random sampling and
frequency matched for age. As well as cases and controls, living
relatives were interviewed face to face or by telephone.
For each proband (case or control), a detailed family history was
systematically recorded for first- and second-degree relatives, and
subsequently checked with living relatives at interview. For the
purpose of sampling cases for mutation screening, individuals who
reported at least one first- or second-degree female relative with
breast cancer were considered to have a ‘family history’.
Verification of every cancer reported in a family by either probands
or relatives was sought through cancer registries, pathology reports,
hospital records, treating clinicians and death certificates. Blood
samples were collected from cases and controls, and from selected
relatives in families with a history of cancer. A total of 467 cases
(response rate 73%) and 408 controls (64%) were studied
(McCredie et al, 1998). Of these, blood samples were available
from 388 cases (60% of all eligible cases) and 294 controls. There
were no differences between cases from whom blood was, or was
not, collected in terms of age, country of birth, or any of the
measured risk factors (Southey et al, 1998).
Table 1 BRCA1 exon 11 primer sequences
Primer name PCR primer sequence Sequencing Region
primer analysedb
11.1 5¢ GGA ATT AAA TGA AAG AGT ATG AGCa 5¢ 789–1140
11.1 3¢ CTC ACA CAG GGG ATC AGC ATT Ca
11.2 5¢ TGA ACA CCA CTG AGA AGC GTG 3¢ 1021–1207
11.2 3¢ GAC ATT CCA AGA CTA CTG AGT GT
11.3 5¢ CAA CAT AAC AGA TGG GCT GGA AGa 5¢ 1129–1411
11.3 3¢ GCC AGT AAG TCT ATT TTC TCT GAA GAA Ca
11.4 5¢ GGT TCT GAT GAC TCA CAT GAT GGGa 5¢ 1363–1590
11.4 3¢ TGT GAG GGG ACG CTC TTG
11.5 5¢ TTG GGA AAA CCT ATC GGA A 5¢ 1561–1796
11.5 3¢ CCA TGA GTT GTA GGT TTC TGC TGa
11.6 5¢ ATC AGG GAA CTA ACC AAA CGG AGa 5¢ 1790–2059
11.6 3¢ CCA TGA GTT GTA GGT TTC TGC TGa
11.7 5¢ AGG CTG AGG AGG AAG TCT TCT ACCa 5¢ 1996–2293
11.7 3¢ CCT GAG TGC CAT AAT CAG TAC CAG Ga 3¢ 2165–2404
11.8 5¢ GTG TTC AAA TAC CAG TGA ACT TA 5¢ 2368–2638
11.8 3¢ TGT TCA CAT TCA AAA GTG 3¢ 2598–2777
11.9 5¢ GCC AGT CAT TTG CTC CGT TTCa 5¢ 2768–3050
11.9 3¢ GGA GCC CAC TTC ATT AGT AC 3¢ 2964–3234
11.10 5¢ CCA AGT ACA GTG AGC ACA ATT A 5¢ 3229–3420
11.10 3¢ CAG GAT GCT TAC AAT TAC TTC CAG Ga
11.11 5¢ TTG AAT GCT ATG CTT AGA TTA GGG Ga 5¢ 3417–3761
11.11 3¢ GTG ATG TTC CTG AGA TGC CTT TGa
11.12 5¢ GAG TCC TAG CCC TTT CAC CCA TACa 5¢ 3744–4123
11.12 3¢ GTG CTC CCA AAA GCA TAC Aa 3¢ 3865–4215
aPrimers described by Friedman et al (1994). bSequence as per Genbank Accession No. U14680.36 MC Southey et al
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Two groups of cases were chosen for BRCA1 sequencing by
random stratified sampling: 47 who reported a family history of
breast cancer, of whom we were able to verify 36 (77%), and 44
who did not report a family history. Variants identified in cases
were tested for in a random sample of 67 controls.
The study was approved by the Institutional Ethics Committees
of The University of Melbourne, The Anti-Cancer Council of
Victoria, and the New South Wales Cancer Council.
DNA preparation
DNA was extracted from stored buffy coat using a Progenome II
DNA extraction kit (Progen, Australia) and stored in TE buffer
(10 mM Tris. HCl/pH 8.0, 1 mM EDTA).
PCR analysis
Each coding exon of BRCA1 (except exon 11) was amplified using
intronic primers based on those described by Simard et al (1994),
located 5¢ and 3¢ to each exon. Exon 11 was amplified in twelve
overlapping PCR fragments. The combinations of oligonucleo-
tides and sequencing strategy necessary to sequence exon 11 are
indicated in Table 1. Exon 7 was also amplified using the above
intronic 5¢ primer and a newly designed intronic 3¢ primer (5¢-
GGC CAT GGT GCG CGT GCC GTG T -3¢) [replacing the
exonic primer described previously (Simard et al, 1994)]. Typical
PCR reactions contained [10 ng DNA, 1´ reaction buffer (Perkin
Elmer), 1.5–2.5 mM magnesium chloride, 0.2 mM each PCR
primer, 0.1 mM dNTPs and 0.5 units Amplitaq DNA polymerase
(Perkin Elmer) in a final volume of 25 ml]. PCR fragments were
amplified in a 96-well format in a Gene Amp PCR system 9600
(Perkin Elmer). After PCR amplification, 5 ml of the reaction
product was analysed via gel electrophoresis and ethidium
bromide staining. The remaining volume (20 ml) was purified
using a Sephaglas Bandprep Kit (Pharmacia Biotech) and eluted
into a final volume of 12–15 ml TE.
Cycle sequencing
Sephaglas purified PCR fragments (6 ml) were sequenced (50% in
both directions) using Amplicycle Sequencing Kits (Perkin Elmer)
incorporating [33P]dATP (NEN). Primers used for PCR amplifica-
tion were used to prime the sequencing reaction for each of the
small exons and, as indicated in Table 1, for exon 11. Sequenced
PCR fragments were analysed using standard 6% polyacryl-
amide/urea sequencing gels on BIO-RAD apparatuses. Samples
were loaded into 48-well combs, typically 12 fragments per gel,
with all 12 A, C, G and T tracks running alongside each other. Gels
were run for 3–6 h before being dried on a slab drier (Bio-Rad)
(without fixation) and exposed to overnight autoradiography. The
normal  BRCA1 sequence was identified, which made up the
background sequencing pattern on the autoradiograph. BRCA1
sequence variants were easily identified as they appeared as
aberrant banding patterns on the normal sequence background.
Fragments containing aberrant sequences were reamplified from
stock DNA of the same individual and the analysis was repeated.
Where possible, individuals identified to be carrying BRCA1
mutations were bled again and the sequence analysis was repeated
for a third time. Sequence variants identified as truncating muta-
tions within exon 11 were further analysed using the protein
truncation test (PTT).
Protein truncation test (PTT)
The PTT within exon 11 was a modification of that described by
Roest et al (1993), including (Seg 3 T7 and Seg 4 T7) primers
described by Hogervorst et al (1995) and reverse primers
described by Friedman et al (1994) using genomic DNA as the
PCR template. Exon 11 was PCR amplified in three overlapping
fragments. PCR fragments (250–500 ng) were then subjected to a
transcription and translation protocol incorporating [35S]methio-
nine (Amersham) and utilizing T7 RNA polymerase, a rabbit retic-
ulocyte lysate and a luciferase control (Promega). An additional
BRCA1 control individual was selected who did not contain a trun-
cating mutation in exon 11 (as assessed by sequencing). Reactions
were analysed via 14% sodium dodecyl sulphate polyacrylamide
gel electrophoresis (SDS-PAGE) on a mini-protean II apparatus
(Bio-Rad). Dried gels were exposed to overnight autoradiography,
enhanced by Amplify fluorographic reagent (Amersham).
Statistical methods
The proportion (P) of cases in the population who carry a germline
BRCA1 mutation/variant/polymorphism was estimated from the
sequencing of N1 cases with, and N2 cases without, a family
history, by P = p1n1/N1 + p2n2/N2 where n1 and n2 are the observed
numbers of mutations/variants/polymorphisms and p1 = 0.3 and
p2 = 1 – p1 = 0.7 are the estimated proportions of all cases in the
population with and without a family history, respectively, based
on the total sample of 467 cases (McCredie et al, 1998). A 95%
confidence interval (supported range) for P was calculated from
the likelihood profile (Clayton and Hills, 1993). The difference
between the proportion of cases and the proportion of controls
with a given polymorphism was assessed by the likelihood ratio
criterion.
RESULTS
Demographic and lifestyle characteristics of the cases and controls
from which subjects were chosen for BRCA1 sequencing are given
in McCredie et al (1998). The main risk factors for early onset
breast cancer are age and having a family history of breast cancer,
and sampling was stratified according to the latter factor. There
was no difference between sequenced and non-sequenced cases in
mean age (35.0 vs. 34.8 years; P = 0.7), or in other established or
putative risk factors for breast cancer measured in our study
(McCredie et al, 1998) including parity, height, weight, age at
Table 2 Presence or absence of a BRCA1 protein-truncating mutation in
women with breast cancer diagnosed before the age of 40 years, by family
history status
BRCA1 Family historya
mutation status
Yes No Total
Yes 1 2 3
No 46 42 88
Total 47 44 91
aFamily history is defined by at least one female first- or second-degree
relative reported to have had breast cancer.BRCA1 mutations and variants in women with breast cancer 37
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menarche and use of oral contraceptives. The percentage of
women born in Australia did not differ between cases sequenced
and controls sequenced (73% vs. 85%; P = 0.06).
Mutations
Table 2 shows that three mutations were detected by sequencing,
and confirmed to be protein-truncating by PTT analysis. They
were: (i) a 1876delC mutation, which terminates translation at
codon 587; (ii) a 3888delGA mutation, which terminates transla-
tion at codon 1265; and (iii) a 3415delC mutation, which terminates
translation at codon 1108. All three mutations were in exon 11.
The 1876delC mutation was found in a case diagnosed in her
late 30s who had a family history of breast cancer. Her mother had
verified breast cancer diagnosed in her late 40s, and it was
reported, but not verified, that her mother’s brother had prostate
cancer. A peripheral blood sample had been collected from the
mother at recruitment. Sequencing of BRCA1 showed, however,
that she did not carry the 1876delC mutation. No DNA was avail-
able from the biological father whose identity, and hence family
cancer history, was unknown.
The 3888delGA mutation was detected in a woman diagnosed
in her 30s, who had no relative with any cancer on either side of
her family. Her sister was in her early 30s and unaffected. Her
mother and an aunt were alive and in their 50s, and her father and
an uncle were both alive and in their 60s. One grandmother died in
her 50s and the other was alive in her 90s, whereas one grandfather
lived to his 80s and the other to his late 60s.
The 3415delC mutation was detected in a woman diagnosed in
her 30s, who also had no relative with any cancer on either side of
her family. Her sister was in her early 30s and unaffected. Her
mother, father, four aunts and two uncles were alive and in their
50s and 60s. One grandmother died in her 50s (cause unknown)
and the other in her 80s, whereas one grandfather died in his 30s
and the other in his 50s.
In our study, 30% of all cases diagnosed before the age of 40
reported a family history in a first- or second-degree relative
(McCredie et al, 1998). Therefore, taking into account the
stratified sampling (Table 2), we estimated that the proportion of
Australian women with breast cancer diagnosed before the age of
40 who carry a germline protein-truncating mutation in BRCA1 is
3.8%, with a 95% confidence interval of 0.3–12.6%.
Rare variants
Table 3 shows that seven rare variants were observed in a total of
11 cases, and two of these variants were also observed in controls.
A T®A variation at nucleotide 172 in exon 2, resulting in a
Met®Lys amino acid change, was observed in a case diagnosed in
her 30s, whose mother had verified breast cancer diagnosed in her
early 50s. No DNA was available from her mother, but as her
father did not possess the variant yet one of her sisters did it is
implied that the mother also had the variant (given that paternity
has been correctly reported).
An intronic C®T variation 49 bp 5¢ of exon 4 was observed in
two cases without a family history, and in four controls.
An intronic A®C variation 2 bp 5¢ of exon 10, and an A®G
variation at nucleotide 760 in exon 10, that results in an Asp®Gly
amino acid change, were both observed in the same case. She was
diagnosed at age 39, and had a family history; her mother was
verified to have had breast cancer diagnosed in her late 40s, and
also shared both these variants. There were no maternal aunts.
Table 3 BRCA1 variants detected
DNA varianta Nucleotide Codon Amino acid Allele frequencyb (no. of alleles)
change change
Cases (91) Controls (67)
Protein truncating mutations
1876 Del C 586 Stop 587 0.003 (1) –
3888 Del GA 1257 Stop 1265 0.008 (1) –
3415 Del C 1099 Stop 1108 0.008 (1) –
Rare variants
172 bp T>A 17 Met>Lys 0.003 (1) –
49 5¢ exon 4 C>T – – 0.016 (2) 0.030 (4)
2 5¢ exon 10 A>C – – 0.003 (1) –
760 A>G 213 Asp>Gly 0.003 (1) –
3238 G>A 1039 Ser>Asn 0.011 (2) –
4654 A>T 1845 Ser>lle 0.003 (1) –
5075 G>A 1652 Met>lle 0.019 (3) 0.007 (1)
Common polymorphisms
34 5¢ exon 8 C>T – – 0.30 (52) 0.23 (31)
58 5¢ exon 9 Del 1 – – 0.21 (53) 0.29 (39)
1186 A>G 356 Gln>Arg 0.07 (12) 0.04 (6)
2201 C>T 694 Ser>Ser 0.21 (40) 0.31 (42)
2430 T>C 771 Leu>Leu 0.21 (40) 0.31 (42)
2731 C>T 871 Pro>Leu 0.20 (39) 0.30 (40)
3232 A>G 1038 Glu>Gly 0.13 (24) 0.32 (43)
3667 A>G 1183 Lys>Arg 0.20 (38) 0.31 (42)
4427 T>C 1436 Ser>Ser 0.21 (39) 0.31 (42)
4956 A>G 1613 Ser>Gly 0.21 (40) 0.31 (42)
aSequence as per Genbank Accession No. U14680. bAdjusted for stratified sampling.A G®A variation at nucleotide 3238 in exon 11, resulting in a
Ser®Asn amino acid change, was observed in two cases. One of
these cases had bilateral breast cancer diagnosed in her 30s, and
had a family history. It was verified that the grandmother on the
mother’s side had breast cancer diagnosed in her early 70s.
Sequencing of germline DNA extracted from the paraffin-
embedded formalin-fixed tumour block revealed that this grand-
mother carried the same variant. The mother also carried the
variant, and was unaffected in her early 60s. The other case with
this variant had no cancer family history; her mother was alive in
her 60s, and her grandmothers lived to their 70s and 90s.
A G®T variation at nucleotide 4654 in exon 15, resulting in a
Ser®Ile amino acid change, was observed in a case diagnosed in
her 30s. Her family history consisted of an unverified report of
breast cancer in the maternal grandmother in her 80s. The mother
also had the variant, and was alive in her late 50s.
A G®A variation in nucleotide 5075 in exon 16, resulting in a
Met>Ile amino acid change, was observed in three cases. One of
these had a family history that was not associated with the variant,
whereas the other two did not have a family history. The variant
was also observed in one control who had a family history; her
maternal aunt had verified breast cancer in her 70s.
Polymorphisms
A total of 12 common variants (polymorphisms) were observed,
two being intronic; see Table 3. For no polymorphism was the
allele frequency in cases greater than in controls, at the nominal
significance level of 0.05.
A case with three rare BRCA1 variants
One case had three rare variants (A®C 2 bp 5¢ of exon 10, A®G
at 760 in exon 10 and G®A at 5075 in exon 16). She shared the
A®C and A®G variants with her mother, who had breast cancer,
and the G®A variant only with her father.
DISCUSSION
Although focused on women with breast cancer diagnosed at a
young age, and despite a full sequencing of the BRCA1 coding
region, we found only a few mutations that could be unequivocally
considered as deleterious (and we confirmed that they were
protein-truncating). This observation is in accord with those of
Langston et al (1996) and Newman et al (1998), who also found
low estimates of the population prevalence of BRCA1 mutations in
early-onset cases. As well as the common polymorphisms seen in
samples of women from multiple-case families and control groups
(Durocher et al, 1996), our sequencing of cases revealed seven
rare variants with either an unknown, or at most small, influence
on susceptibility to early-onset breast cancer.
Interpreting the clinical significance of variants in the coding
region of BRCA1 is not always straightforward. First, protein-
truncating mutations are presumed to be deleterious, based on
functional considerations, and on the observation that these types
of mutations segregate with the disease in families containing
multiple cases of breast and/or ovarian cancer (Shattuck-Eidens et
al, 1995). It is usually considered that if a protein-truncating
mutation is observed in a case, then it is ‘the’ cause of the cancer.
On a population basis, however, the percentage of such cases
attributable to other causes is not zero, and, although small, it
increases with age at diagnosis.
Second, polymorphisms (variants with no obvious functional
effect, or that appear reasonably often with a similar frequency in
cases as in controls) are not considered to have a major influence
on cancer risk. Small effects (such as relative risks less than 2) can
only be refuted by large population-based studies (see Bishop and
Hopper, 1997).
Finally, those rare variants, or missense mutations, that are not
obviously deleterious are very difficult to interpret. Extremely
large population-based studies may be needed to exclude a modest
effect on disease risk. Even if a rare variant is observed in controls,
it may still have an effect on cancer risk (Bishop and Hopper,
1997). And, even if it is observed to track with disease within a
family, it cannot necessarily be presumed to be of aetiological
significance; although rare in the population it will be common
within that family. Nevertheless, the proportion of cancer in the
population attributable to rare variants is likely to be minimal. An
important step in evaluating the clinical relevance of rare variants
would be a functional assay utilizing eukaryotic cell systems.
In the interim, one way of trying to understand the significance of
rare alleles and putative mutations is to pool data from comparable
studies and conduct meta-analyses. One step in this direction is for
researchers to report identified variants to a central registry, such as
the Breast Cancer Information Core (BIC) on the World Wide Web
(http://www.nhgri.nih.gov/Intramural_research/Lab_transfer/bic).
None of the three protein-truncating mutations we observed have
yet been reported to the BIC. Each of the three rare variants not
found on the BIC was only observed in one case, and each caused an
amino acid change. The two polymorphisms we observed that were
not on the BIC were intronic.
Although classified in its sole report on the BIC as a possible
mutation, we observed the intronic C®T variation 49 bp 5¢ of exon
4 in 6% of controls and 3% of cases. Most of the five reports on the
BIC of the G®A variation in nucleotide 5075, which we observed
in 4% of cases and 1% of controls, considered it to be a polymor-
phism. The G®A variation at nucleotide 3238 in exon 11 has been
reported eight times on the BIC as having unknown significance,
however in one of these reports it was observed in 3% (7/242) of
cases and in 4% (3/82) of controls (Durocher et al, 1996). We
observed it in a case and her grandmother who had breast cancer in
her 70s, but her obligate-carrier mother was unaffected in her early
60s. Therefore, none of the above three variants observed by us and
others is likely to have a strong effect on early onset breast cancer
risk, although a small effect cannot be categorically excluded.
The intronic A®C variation 2 bp 5¢ of exon 10, described only
once on the BIC and then as a possible splice-site mutation, was
observed in one case and her affected mother. The case and her
mother also shared the A®G variation in exon 10, but this variant
has not been reported on the BIC.
Although not on the BIC, our single observation of a T®A varia-
tion at nucleotide 172, which causes a Met®Lys amino acid change,
may be of interest. A T®C variation at this same site, which causes a
Met®Thr amino acid change, was observed in 1 out of 80 cases and
0 out of 73 controls in a population-based study of young women
with breast cancer (Langston et al, 1996). That case apparently did
not have a family history. The G®T variation at 4654, seen in one
case and her father, also has not been reported on the BIC.
Therefore, for none of the variants we observed is there
evidence for a strong effect on breast cancer susceptibility. We
observed, at most, four rare variants with any potential to have a
high risk, but they are obviously very uncommon. Consequently,
although we cannot discount that on an individual basis they may
38 MC Southey et al
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be important, on a population basis such rare alterations to BRCA1
are of little consequence in that they are likely to explain no more
than a minimal proportion of breast cancer in the population.
For the common polymorphisms, the allele frequencies we
observed are consistent with those reported in other populations
(Durocher et al, 1996). Given our sample sizes and the allele
frequencies in controls of about 0.2–0.3, we had 80% power to
detect increased risks of fourfold or more at the 0.05 level of
significance for the polymorphisms. Interestingly, the allele
frequencies for the exon 11 polymorphisms in pairwise linkage
disequilibrium observed in control samples from Utah and Quebec
are quite similar to those from our Australian sample.
The different estimates of the prevalence of mutations in BRCA1
reported in the literature to date should not be overinterpreted. First,
populations vary from one another in their racial and ethnic charac-
teristics and origins, so one might anticipate that real differences
exist both within and between populations. For example, it is
already known that in the USA the Ashkenazi Jewish population
has about 20 times the prevalence of mutations in BRCA1 and
BRCA2 than thought to apply to the whole population (Struewing et
al, 1997). Second, the imprecision of estimates – a consequence of
the surprisingly small number of cases being found to be carriers –
cannot be overlooked; see the large confidence intervals (where
reported) in the Introduction and Results sections. Mutation detec-
tion, especially if it is to have close to 100% specificity (as we have
attempted in this study), is very expensive and time-consuming
using current technology. It is likely that this may change in the
next decade (Hacia et al, 1996), so it behoves researchers to apply
epidemiological rigour to the collection of large and carefully char-
acterized population samples, paying careful attention to matching
considerations (Bishop and Hopper, 1997).
The lack of family history of breast or ovarian cancer in our
mutation-carrying cases, and other reports of mutation-carrying
cases not necessarily having a family history of breast cancer (e.g.
Langston et al, 1996), demonstrates that in the population setting a
family history may be a weak predictor of BRCA1 mutation status.
Only families with an extensive history of breast and/or ovarian
cancer appear to have more than a small chance of harbouring
BRCA1 mutations (Easton et al, 1993). It also raises concern about
the average penetrance of those BRCA1 mutations causing breast
cancer in the population.
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